Keyphrases
18F-FDG PET-CT
100%
Predictive Value
100%
Diffuse Large B-cell Lymphoma (DLBCL)
100%
Early Response
100%
International Harmonization Project
100%
Positive Predictive Value
37%
Negative Predictive Value
37%
Progression-free Survival
25%
Overall Survival
25%
18F-fluorodeoxyglucose (18F-FDG)
25%
Standardized Uptake Value
25%
18F-fluorodeoxyglucose Positron Emission Tomography (18F-FDG PET)
25%
Advanced Stage
25%
Event-free Survival
25%
End of Therapy
25%
Prednisone
12%
Remission
12%
Initial Treatment
12%
Chemotherapy
12%
2-cycles
12%
Positron Emission Tomography-computed Tomography (PET-CT)
12%
Lymphoma
12%
Prognostic Value
12%
Rituximab
12%
Patient Management
12%
Response Criteria
12%
Treatment Course
12%
Doxorubicin
12%
Cyclophosphamide
12%
Low Positive
12%
Immunochemotherapy
12%
Value Measurement
12%
FDG-avid
12%
FDG-PET Scan
12%
International Harmonization Project Criteria
12%
Pharmacology, Toxicology and Pharmaceutical Science
Diffuse Large B Cell Lymphoma
100%
Fluorodeoxyglucose F 18
100%
International Harmonization
100%
Polyethylene Terephthalate
100%
Progression Free Survival
15%
Prospective Study
15%
Overall Survival
15%
Chemotherapy
15%
Event Free Survival
15%
Prednisone
7%
Remission
7%
Rituximab
7%
Doxorubicin
7%
Cyclophosphamide
7%
Vincristine
7%
Medicine and Dentistry
Positron Emission Tomography-Computed Tomography
100%
Fluorodeoxyglucose F 18
100%
Diffuse Large B-Cell Lymphoma
100%
Polyethylene Terephthalate
23%
Progression Free Survival
15%
Overall Survival
15%
Prospective Study
15%
Event Free Survival
15%
Standardized Uptake Value
15%
Chemotherapy
15%
Rituximab
7%
Doxorubicin
7%
Cyclophosphamide
7%
Prednisone
7%
Vincristine
7%
Immunology and Microbiology
B Cell
100%
Positron Emission Tomography-Computed Tomography
100%
Overall Survival
20%
Progression Free Survival
20%
Event Free Survival
20%
Rituximab
10%
Prednisone
10%
Cyclophosphamide
10%
X-Ray Computed Tomography
10%